EXACT Sciences Corporation (NASDAQ:EXAS) announced that data supporting its stool DNA (sDNA) screening platform for colorectal cancer and other screening techniques for the detection of additional gastrointestinal cancers and diseases will be presented in five posters at Digestive Disease Week (DDW) 2015, taking place May 16-19 in Washington D.C. Recently approved by the U.S. Food and Drug Administration (FDA), Exact Sciences’ noninvasive screening test Cologuard® uses sDNA technology to help detect the presence of colorectal cancer and precancer. Exact Sciences’ technologies can be seen at the show at booth #1552.

“Building on the publication of strong clinical data supporting sDNA technology, followed by the FDA approval of Cologuard, we are pleased to see new clinical evidence backing this important screening option at this year’s DDW conference,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Studies like these will continue to drive awareness and adoption of Cologuard and provides Exact Sciences with the preliminary data needed to advance our product pipeline.” (Original Source)

Shares of Exact Sciences closed today at $22.97, down $0.04 or 0.17%. EXAS has a 1-year high of $29.97 and a 1-year low of $11.81. The stock’s 50-day moving average is $22.51 and its 200-day moving average is $24.73.

On the ratings front, Exact Sciences has been the subject of a number of recent research reports. In a report issued on May 5, JMP analyst J T Haresco reiterated a Hold rating on EXAS, with a price target of $31, which represents a potential upside of 35.0% from where the stock is currently trading. Separately, on the same day, Roth Capital’s Chris Lewis reiterated a Buy rating on the stock and has a price target of $28.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, J T Haresco and Chris Lewis have a total average return of 8.5% and 2.8% respectively. Haresco has a success rate of 53.3% and is ranked #1423 out of 3602 analysts, while Lewis has a success rate of 47.4% and is ranked #1501.

In total, 4 research analysts have assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $22.97 which is 16.9% above where the stock opened today.

Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a noninvasive, patient friendly screening test called Cologuard(R).